Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

20.83 -0.85 (-3.92%)
Streaming Delayed Price Updated: 12:32 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Where Denali Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst ↗
B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a  
Via Benzinga
News headline image
Analyst Expectations for Denali Therapeutics's Future ↗
 
Via Benzinga
News headline image
Where Denali Therapeutics Stands With Analysts ↗
 
Via Benzinga
Analyst Expectations for Denali Therapeutics's Future ↗
Within the last quarter, Denali Therapeutics (NASDAQ:DNLI) has observed the following analyst ratings: 
Via Benzinga
News headline image
Why Shares of Denali Therapeutics Are Up Monday ↗
Analysts maintained their buy ratings on the clinical-stage biotech company. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗
 
Via Benzinga
News headline image
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now ↗
With longevity back in the news, many investors are wondering which biotech stocks to buy to best cash in on the growing trend. 
Via InvestorPlace
News headline image
Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker ↗
Denali Therapeutics Inc (NASDAQ: DNLI) announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 IDS in children with  
Via Benzinga
News headline image
Where Denali Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Where Denali Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Expert Ratings for Denali Therapeutics ↗
 
Via Benzinga
News headline image
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure ↗
 
Via Benzinga
News headline image
Biogen Moves Deeper In Alzheimer's With Denali ↗
Biogen exercised their rights to a Denali Alzheimer's drug. What does this mean longer term to the field and the companies? 
Via Talk Markets
News headline image
Denali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome Study ↗
 
Via Benzinga
News headline image
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday ↗
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Netflix, Biogen And Other Big Gainers From Wednesday ↗
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022 ↗
 
Via Benzinga
News headline image
4 Undervalued Biotech Stocks to Add to Your Buy List ↗
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns. 
Via InvestorPlace
News headline image
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
News headline image
AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship ↗
Flagship Pioneering is swiping one of AbbVie's biggest names. 
Via Investor's Business Daily
News headline image
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
7 F-Rated Stocks to Avoid During the Downturn ↗
It's easy to find hard hit stocks in this market, but what's harder to determine is which stocks are truly F-rated stocks among the losers. 
Via InvestorPlace
News headline image
Denali Receives Formal Letter Regarding FDA Hold On Alzheimer's Potential Program ↗
As previously announced, Denali Therapeutics Inc (NASDAQ: DNLI) was informed via e-mail communication from the FDA that DNL919 (ATV:TREM2) Investigational New Drug (IND... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.